ERBB2 and endometrial cancer: The epidermal growth factor receptor 2 (ERBB2, formerly HER2)–targeting antibody drug conjugates (vic-)trastuzumab duocarmazine and trastuzumab deruxtecan have recently been tested in endometrial cancer (EC), including patients with ERBB2 immunohistochemistry score 1+ and 2+–expressing tumors.